The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
 
Hiroshige Yoshioka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Kyowa Kirin Co., Ltd.; Lilly; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Delta-Fly Pharma
 
Toyoaki Hida
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clovis Oncology; Kissei Pharmaceutical; Lilly; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Servier (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroshi Nokihara
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical
Consulting or Advisory Role - MSD
Research Funding - AstraZeneca (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst)
 
Masahiro Morise
Speakers' Bureau - AstraZeneca; Chugai/Roche; Lilly; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Young Hak Kim
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical
 
Takashi Seto
Employment - Precision Medicine Asia
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Covidien; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Loxo (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
 
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Toru Kumagai
Consulting or Advisory Role - Nitto Denko; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Nippon Boehringer Ingelheim; Taiho Pharmaceutical
Other Relationship - Pfizer
 
Katsuyuki Hotta
Honoraria - AZD; Chugai Pharma; Lilly; MSD Oncology; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AZD; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD
 
Satoshi Watanabe
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim
 
Koichi Goto
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; MSD K.K.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo
 
Miyako Satouchi
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; Merck; MSD Oncology; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); EPS Holdings (Inst); Ignyta (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Abbvie; Amgen; Amgen; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Kyorin; Kyowa Kirin Co., Ltd.; Lilly; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; YODOSHA
Consulting or Advisory Role - Kyorin; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Covance (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tetsuya Mitsudomi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo; Ethicon; Guardant Health; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermofisher Scientific Biomarkers
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Life Technologies; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Lilly (Inst); Maruho (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Toppan Printing Co. (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)
 
Takuya Yoshimoto
Employment - Chugai Pharma
Stock and Other Ownership Interests - Chugai Pharma
 
Tomohide Tamura
Honoraria - Boehringer Ingelheim; Chugai Pharma; CMIC; Lilly; MSD; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical